NCT07386847Completed
A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer
Real-world Treatment Patterns and Effectiveness Among Patients With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
Source: ClinicalTrials.gov · Last updated 28 May 2026
Brief summary (registry, in English)
Bladder cancer (urothelial carcinoma) is a disease where cells in the bladder grow out of control. The bladder is an organ in the lower part of the body that stores urine. When someone has bladder cancer, abnormal cells form in the bladder and can spread to other parts of the body if not treated. Bladder cancer that has spread outside the bladder is called advanced or metastatic bladder cancer. The purpose of this study is to examine how long it takes for adults with advanced or metastatic bladder cancer to experience worsening of their disease following their first treatment . The researchers will also describe which medicines these patients use as their first treatment for the disease. This is a real-world study, not a clinical study. This means that researchers will look at what happens when patients receive the treatments prescribed by their own doctor as part of their usual healthcare treatment. In this study, researchers will use information from cancer clinics (Flatiron Health electronic health records). The study will include patients' information from the database who: * Were identified to have advanced or metastatic bladder cancer. * Started their first treatment after 01 Apr 2023. * Were 18 years of age or older when they were diagnosed with advanced disease.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1 (actual)
- First submitted
- 28 Jan 2026
- Start date
- 12 Feb 2026
- Primary completion date
- 30 Mar 2026
- Lead sponsor
- Pfizer
- Diseases
- Bladder cancer
- NCT number
- NCT07386847
What you commit to
- Study type: Observational
- Participants enrolled: 1
- From 12 Feb 2026 to the primary completion date, 30 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Primary site of disease other than bladder, renal pelvis, ureter, or urethra
Other
- Histology other than transitional cell (urothelial) carcinoma.
- Clinical trial participation.
Who the study is looking for
- Adults (18 years or older) diagnosed with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Flatiron Health database.
- Started first line systemic treatment for la/mUC during the study period.
- Received care in the United States, as the study is U.S.-based.
- Has sufficient available real-world data to assess treatment patterns and outcomes (e.g., treatment dates, follow-up, response/survival information).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Office Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.